Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALVAC-hB7.1
- Development stage
- Phase 1
- Lead developer
- National Cancer Institute
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Cell Therapies, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous, Intradermal
01
Overview
ALVAC-hB7.1 is a therapeutic cancer vaccine platform that utilizes a recombinant, non-replicating canarypox virus (ALVAC) engineered to express the human B7.1 (CD80) costimulatory molecule[2][3][8]. The vaccine is designed to enhance antitumor immune responses by increasing the expression of costimulatory signals on autologous tumor cells, thereby promoting T-cell activation and cytotoxicity against cancer cells[8]. In clinical settings, tumor cells harvested from patients are infected with ALVAC-hB7.1 ex vivo and then re-administered as an autologous cell-based vaccine[8]. This approach has been investigated primarily in ovarian cancer and melanoma, aiming to boost host immunity against tumors by improving antigen presentation and T-cell priming through CD80-mediated costimulation[2][6][8].
- Other names
- AUT-OV-ALVAC-hB7.1AUT-OV-ALVAC-hB-7.1AUT-OV-ALVAC-hB 7.1
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)CD28 (Cluster of Differentiation 28)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on ALVAC-hB7.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALVAC-hB7.1.